Isolated NPM1 mutations and biallelic CEBPα aberrations are rarely found in pediatric AML patients compared to adults, but they still seem to be associated with improved outcomes [48, 49], and patients carrying these abnormalities should not be offered allo-HSCT in CR1 [9, 18]. This evidence concerns the gene CEBPA and acute myeloid leukemia.